All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

In 2011, a joint IASLC/ATS/ERS working group introduced a new classification of human lung adenocarcinoma \[[@pone.0206132.ref001]\]. This new classification defined five different histological growth patterns within the group of conventional invasive adenocarcinomas: lepidic (corresponding to the former non-mucinous bronchioloalveolar pattern), acinar, papillary, micropapillary (newly added) and solid predominant adenocarcinoma. Overall tumor classification was suggested to be done according to the predominant pattern with additional documentation of the percentage distribution of all evident architectures \[[@pone.0206132.ref001],[@pone.0206132.ref002]\]. The five growth patterns should be characterised by their typical architecture, but also by variable tumor biological behaviour. The predominant pattern has relevant influence on the disease-free and long-term survival of patients. Whereas lepidic predominant adenocarcinoma seems to be the one with the best prognosis, the micropapillary and solid architectures are associated with a particularly poor prognosis \[[@pone.0206132.ref003]--[@pone.0206132.ref007]\]. On the molecular level, lung adenocarcinomas have been characterised by diverse transcriptional profiles \[[@pone.0206132.ref008]--[@pone.0206132.ref010]\]. Three molecular subtypes (bronchoid/terminal respiratory, magnoid/proximal-proliferative and squamoid/proximal-inflammatory) were defined and successfully verified across several microarray and sequencing datasets \[[@pone.0206132.ref011]--[@pone.0206132.ref013]\]. Such molecular profiles are used to decipher prognostic/predictive biomarkers and therapeutic target sites specific for patient subgroups. However, the present transcriptomic profiles of lung adenocarcinoma do not necessarily reflect the distinct histological architectures. Our study combined tissue microdissection and molecular profiling of the five lung adenocarcinoma growth patterns in order to precisely identify specific genes signatures. Selected biomarkers and drug targeted candidates were validated by immunohistochemistry (IHC) in the lepidic and solid growth patterns.

Materials and methods {#sec007}
=====================

Patients {#sec008}
--------

Cryopreserved tumor tissue of 48 patients was selected based on the histopathological findings following surgery for lung adenocarcinoma. All tumor sections were analysed for their growth patterns including lepidic (10), acinar (10), papillary (9), micropapillary (9) and solid (10) architecture. Cryopreserved tumor tissue was provided by lung biobank Heidelberg, a member of the biomaterial bank Heidelberg (BMBH) and of the biobank platform of the German Center for Lung Research (DZL) (Ethical Approval Number: 2070/2001). Tumor sections from an additional 20 patients were used for IHC validation. Paraffin tissue was provided by the tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the ethics committee of Heidelberg University (Ethical Approval Numbers: 206/2005 and 207/2005). All data was fully anonymized before we accessed them. All patients gave their written informed consent to have samples from their medical records used in research.

Laser-capture microdissection {#sec009}
-----------------------------

The isolation of tumor areas representing a specific growth pattern was performed by laser capture microdissection (PALM's LMPC technology, Carl Zeiss Microscopy GmbH, Göttingen, Germany). Fresh frozen tumor samples were cut in 18 μm thick sections and applied to ZEISS Membrane Slides 1.0 PEN (polyethylene naphthalate), baked for 3.5 h at 180° C, irradiated with UV light (312 nm) for 30 min and cooled to -22°C just before use. The tissue sections were stained with 1% cresyl violet (Sigma) for 15 s. Using the RoboLPC method, between 4 and 10 mm^2^ of cells were cut out \[[@pone.0206132.ref014]\]. The tissue areas of interest were circumscribed electronically under the microscope, cut automatically by cold laser ablation and catapulted into an opaque ZEISS AdhesiveCap 500 by damage-free laser-induced propulsion \[[@pone.0206132.ref015]\]. The composition (frequencies) of all 5 growth patterns in each of the 48 tumors has been analyzed ([Table 1](#pone.0206132.t001){ref-type="table"}).

10.1371/journal.pone.0206132.t001

###### Percentage distribution of growth patterns.

![](pone.0206132.t001){#pone.0206132.t001g}

  [Sample]{.ul}   [Microdissected growth pattern]{.ul}   [solid]{.ul}   [acinar]{.ul}   [papillary]{.ul}   [micropapillary]{.ul}   [lepidic]{.ul}
  --------------- -------------------------------------- -------------- --------------- ------------------ ----------------------- ----------------
  LC01            acinar                                 0              75              0                  0                       25
  LC02            acinar                                 0              80              10                 5                       5
  LC03            acinar                                 0              80              0                  0                       20
  LC04            acinar                                 0              95              5                  0                       0
  LC07            acinar                                 0              90              10                 0                       0
  LC09            acinar                                 0              70              20                 0                       10
  LC15            acinar                                 0              80              20                 0                       0
  LC19            acinar                                 10             70              20                 0                       0
  LC26            acinar                                 0              95              0                  0                       5
  LC36            acinar                                 0              25              70                 0                       5
  LC06            lepidic                                0              5               0                  0                       95
  LC18            lepidic                                80             0               0                  5                       15
  LC23            lepidic                                0              30              10                 0                       60
  LC27            lepidic                                0              45              30                 0                       25
  LC30            lepidic                                0              0               0                  5                       95
  LC32            lepidic                                0              0               10                 0                       90
  LC33            lepidic                                30             30              0                  0                       40
  LC34            lepidic                                0              10              0                  0                       90
  LC43            lepidic                                15             10              15                 10                      50
  LC47            lepidic                                0              0               0                  20                      80
  LC08            micropapillary                         0              0               10                 10                      80
  LC14            micropapillary                         0              80              0                  20                      0
  LC29            micropapillary                         0              75              5                  20                      0
  LC31            micropapillary                         0              80              0                  20                      0
  LC35            micropapillary                         5              30              20                 15                      30
  LC45            micropapillary                         5              20              5                  40                      30
  LC37            micropapillary                         60             0               0                  40                      0
  LC41            micropapillary                         0              70              5                  5                       20
  LC42            micropapillary                         0              60              30                 10                      0
  LC17            papillary                              15             25              40                 20                      0
  LC22            papillary                              0              70              10                 5                       15
  LC24            papillary                              0              0               60                 20                      20
  LC28            papillary                              10             80              10                 0                       0
  LC44            papillary                              0              65              5                  5                       25
  LC46            papillary                              0              20              20                 0                       60
  LC38            papillary                              10             40              10                 0                       40
  LC39            papillary                              10             30              20                 10                      30
  LC40            papillary                              0              0               80                 0                       20
  LC05            solid                                  70             20              10                 0                       0
  LC10            solid                                  95             0               5                  0                       0
  LC11            solid                                  100            0               0                  0                       0
  LC12            solid                                  80             20              0                  0                       0
  LC13            solid                                  100            0               0                  0                       0
  LC16            solid                                  60             40              0                  0                       0
  LC20            solid                                  95             5               0                  0                       0
  LC21            solid                                  40             60              0                  0                       0
  LC25            solid                                  80             20              0                  0                       0
  LC48            solid                                  80             20              0                  0                       0

[Table 1](#pone.0206132.t001){ref-type="table"} shows the percentage distribution of the 5 growth patterns in 48 fresh frozen tumor samples used for microdissection.

Microarray experiments {#sec010}
----------------------

Total RNA from microdissected adenocarcinoma tissue sections was extracted and quantified using the RNeasy protocol (Qiagen, Hilden, Germany) according to the manufacturer's instructions. For RNA quality assessment the Agilent 2100 Bioanalyzer System together with the Agilent RNA 6000 Nano Kit was used according to the manufacturer's instructions (Agilent Technologies, Santa Clara, CA, USA). About 20 ng of total RNA was prepared for microarray hybridisation using the MessageAmp^TM^ Premier RNA Amplification Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Fragmented biotinylated amplificated RNA was hybridised on Illumina HumanHT-12 v4 Expression Bead Chip including more than 47,000 Probes (Illumina, San Diego, CA, USA). Processing of the Illumina microarray data was performed using the opensource pipeline "Lumi" \[[@pone.0206132.ref016]\]. More specifically, this pipeline comprises background correction, quantile normalization, model based variance stabilization (PMID 18178591) and detection p-value based present/absent calling. For the following analysis only Entrez ID allocated transcripts with a presence call in each sample of at least one of the studied patient subgroups were considered.

The microarray dataset has been deposited, MIAME compliant, into the NCBI Gene Expression Omnibus database (GSE58772).

Molecular subtype assignment was done as previously described: TCGA data was DESeq normalised and reduced to the 5761 genes, which could be mapped to the data studied here \[[@pone.0206132.ref011]--[@pone.0206132.ref013],[@pone.0206132.ref017]\]. Datasets were first Blom-transformed and subsequently adjusted by an empirical Bayes approach to allow for an integration of the data studied here and the TCGA data \[[@pone.0206132.ref018],[@pone.0206132.ref019]\]. Genes were further reduced to the overlap with the previously reported signature \[[@pone.0206132.ref012]\]. Based on the resulting 260 genes, an SVM classifier was trained on the TCGA data in order to predict expression subtypes defined in 12 \[[@pone.0206132.ref012]\]. The prediction performance of the classifier was evaluated via 10-fold cross-validation, yielding an estimated prediction accuracy of the expression subtype of around 90%. The final SVM model was then asked to make predictions for each sample in our dataset. Respective expression subtype predictions (class probabilities) were illustrated by a clustered heatmap.

Differential expression of genes was determined using the R package "LIMMA" \[[@pone.0206132.ref020]\]. The overall significance of a signature was assessed via a "global test" \[[@pone.0206132.ref021]\]. The global test is a set based method, which tries to reject the null hypothesis that all genes in set of interest (in our case all signature genes) show no association to a defined clinical outcome or grouping. Gene ontology statistics were analysed using GOstat \[[@pone.0206132.ref022]\].

Immunohistochemistry (IHC) {#sec011}
--------------------------

IHC was done for the validation of identified differentially expressed genes. Additional tissue sections from 20 tumors that had been used for the microarray experiment and another 20 specimens from other tumors with solid and lepidic growth patterns were stained with the corresponding antibodies for *ITPKA (inositol-1*,*4*,*5-trisphosphate-3-kinase-A)* (polyclonal anti-rabbit ITPKA, 1/100, Atlas, Stockholm, Sweden), *PFKP (phosphofructokinase*, *platelet)* (polyclonal anti-rabbit PFKP, 1/50, (Thermo Fisher Scientific, Waltham, MA, USA), *ERRFI1 (MIG6*, *mitogen-inducible gene 6)* (polyclonal rabbit anti-ERRFI1, 1/100, Atlas, Stockholm, Sweden) and *angiogenin (ANG)* (polyclonal rabbit anti-angiogenin, 1/100, Abcam, Cambridge, United Kingdom) using an automated staining protocol on the DAKO autostainer (antigen retrieval with citrate buffer pH 6.0). Positive control tissue sections were chosen according to the manufacturers' antibodies information, i.e. cerebral cortex for *ITPKA*, kidney for *PFKP*, breast cancer for *ERRFI1*, and liver for *angiogenin*. Isotype- and concentration-matched control antibodies (Dako, Hamburg, Germany) served as negative controls.

Semi-quantitative evaluation of protein expression was done using the H-Score method according to Pirker et al \[[@pone.0206132.ref023]\]. The percentage of tumor cells at different staining intensities was determined by visual assessment at 200-fold magnification, with the score calculated using the formula 1 x (% of 1+ cells) + 2 x (% of 2+ cells) + 3 x (% of 3+ cells) \[[@pone.0206132.ref023],[@pone.0206132.ref024]\]. Samples were classified as negative (H-Score 0--50), weakly positive (H-Score 51--100), moderately positive (H-Score 101--200) or strongly positive (H-Score 201--300). The average H-Score values for each growth pattern and each antibody staining were calculated and compared.

Results {#sec012}
=======

Molecular profiling of IASLC/ATS/ERS classified growth patterns {#sec013}
---------------------------------------------------------------

In total microdissected tissue sections of 48 specimens were addressed for RNA extraction and microarray experiments. RIN (RNA integrity number) values between 7 and 8 indicate sufficient RNA quality of microdissected tissues (mean RIN 7.5, SD 0.86) for microarray analysis ([S1 Fig](#pone.0206132.s001){ref-type="supplementary-material"}). Microarray analyses between the five different growth patterns resulted in numerous differentially expressed genes between the solid architecture and other patterns ([S1 Table](#pone.0206132.s005){ref-type="supplementary-material"}). Only a few solid-independent comparisons (e.g. papillary vs. micropapillary) indicated significant transcriptome differences. In the following, we focused on the gene signature between the solid and lepidic pattern associated with different clinical outcomes. Earlier, we tested all 48 adenocarcinoma transcriptomes according to their similarities to previously reported gene expression subtypes \[[@pone.0206132.ref012]\]. Supervised classification using 260 informative genes from the Wilkerson signature showed that our 48 samples could be assigned to each of the three classes proximal-inflammatory (PI), proximal-proliferative (PP) and terminal respiratory unit (TRU) with high confidence ([S2 Fig](#pone.0206132.s002){ref-type="supplementary-material"}). Furthermore, the unsupervised multidimensional scaling plot of the joint expression data from our samples and the TCGA data indicated, that all our samples fell clearly within the distribution of each of the three classes ([S3 Fig](#pone.0206132.s003){ref-type="supplementary-material"}). Altogether, the solid patterns (90% of specimens) clearly assigned for the PI subtype, acinar patterns (70%) predominantly assigned for the PP and lepidic patterns (70%) for the TRU subtype ([S2 Table](#pone.0206132.s006){ref-type="supplementary-material"}). However, differentially expressed genes between the microdissected histological patterns differed from previously reported gene signatures in adenocarcinoma subtypes, as highlighted for the solid-lepidic gene signature in the following paragraph.

Differences in gene expression, cellular processes and signalling pathways in the solid and lepidic patterns {#sec014}
------------------------------------------------------------------------------------------------------------

Comparison of the transcriptomic activity between the solid and lepidic patterns revealed 705 up- and 110 downregulated non-redundant genes (FDR (false discovery rate) 5%, fold change \>1.5 or \< 0.66) ([S3 Table](#pone.0206132.s007){ref-type="supplementary-material"}). A clear separation of the specimens of both patterns could be confirmed by hierarchical clustering ([S4 Fig](#pone.0206132.s004){ref-type="supplementary-material"}). Furthermore, only 25 of 815 deregulated genes (3%) overlapped with the reported 506 LAD predictor genes classifying the molecular subtypes \[[@pone.0206132.ref012]\]. Similarly, further reported sets of differentially expressed genes between intrinsic molecular subtypes displayed a poor overlap ([S4 Table](#pone.0206132.s008){ref-type="supplementary-material"}).

Gene ontology analysis suggested several biological processes, which are linked to overrepresented, upregulated genes in the solid pattern. Cancer-associated processes included cell motility, proliferation, cell cycle and negative regulation of apoptosis ([Table 2](#pone.0206132.t002){ref-type="table"}).

10.1371/journal.pone.0206132.t002

###### Gene ontologies.

![](pone.0206132.t002){#pone.0206132.t002g}

  [GO]{.ul}    [GO as name]{.ul}                                   [Genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                             [Groupcount]{.ul}   [Totalcount]{.ul}   [Pvalue]{.ul}
  ------------ --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------- ---------------
  GO:0015031   protein transport                                   mtx1; sdcbp; ap3b1; lgtn; zw10; tomm40; kpna4; fbxo34; kpna6; pttg1ip; vps35; stx3; tpr; srp19; trpc4ap; stx6; mtx2; nup37; nxt1; snapin; kdelr3; sec22b; rab11fip5; clta; xpo1; ctsa; arl6ip1; rab9a; stat1; bcl6; chchd4; arfgap1; gdi1; copb2; mcm3ap; chmp1b; bcl3; rab22a; rab8a; nup205; atg16l1; tmed2; exoc4; stxbp2; vps37c; unc50; sec31a; exoc7; tomm20; ap2m1; sels; aftph   52                  866                 2,80E-18
  GO:0006915   apoptosis                                           pmaip1; glo1; pdcd6; fadd; mrps30; tubb2c; api5; casp2; ripk2; igfbp3; rnf34; rb1cc1; tnfrsf12a; mcl1; dpf2; rtkn; trib3; becn1; pdcl3; smndc1; map1s; axin1; puf60; sema4d; tnfrsf21; tia1; acvr1; ctnnbl1; litaf; arhgdia; qrich1; raf1; bcl6; atg12; stat1; bag3; ywhaz; dnajb6; bcl3; mrpl41; hspa1a; ikbkg; ube2z; ifih1; dap3; tfdp1; tax1bp1; elmo2; rasa1                        49                  855                 5,85E-16
  GO:0006396   RNA processing                                      imp3; exosc1; bop1; hnrpul1; ints5; utp6; prpf4; ddx56; magoh; nsun2; prpf19; wbp11; ints8; u2af1; sf3b4; rbm5; hnrnpr; sf3b2; prpf3; dkc1; raly; sfrs17a; snrpb2; smndc1; u2af2; rbm22; pabpc1; adar; puf60; fars2; rnps1                                                                                                                                                               31                  525                 1,65E-10
  GO:0008380   RNA splicing                                        prpf4; wbp11; magoh; prpf19; u2af1; sf3b4; hnrnpr; sf3b2; prpf3; raly; sfrs17a; snrpb2; smndc1; u2af2; rbm22; puf60; pabpc1; rnps1                                                                                                                                                                                                                                                       18                  225                 6,84E-06
  GO:0009615   response to virus                                   bcl3; becn1; hnrpul1; banf1; isg15; stat1; ifih1; ifnar2; mx2; irf3; xpo1; tbk1                                                                                                                                                                                                                                                                                                          12                  98                  8,32E-06
  GO:0006605   protein targeting                                   bcl3; srp19; sdcbp; ap3b1; nup205; arl6ip1; bcl6; nxt1; stat1; kpna4; tomm20; tomm40; kpna6; pttg1ip; mcm3ap; tpr; xpo1                                                                                                                                                                                                                                                                  17                  218                 1,80E-05
  GO:0000902   cell morphogenesis                                  nrp1; net1; sdcbp; bcl6; cap1; e2f4; igfbp3; cyfip1; rb1cc1; baiap2l1; tbce; tnfrsf12a; c20orf20; ogfr; top2b; ryk; plxna3; map1s; sema4d; sipa1; smad4; rasa1; dgkd                                                                                                                                                                                                                     23                  478                 3,87E-05
  GO:0022008   neurogenesis                                        nrp1; map2k1; nptn; prpf19; cyfip1; tbce; tnfrsf12a; tubb3; cdk5rap1; eif2b2; top2b; ryk; pxmp3; map1s; eif2b4; plxna3; sema4d; ngrn                                                                                                                                                                                                                                                     18                  262                 4,41E-05
  GO:0022613   ribonucleoprotein complex biogenesis and assembly   imp3; ebna1bp2; exosc1; mtif3; bop1; lgtn; utp6; ddx56; wbp11; eif2b2; dkc1; gnl2; nip7; smndc1; eif2b4; eif4h; eif3b                                                                                                                                                                                                                                                                    17                  246                 6,98E-05
  GO:0043066   negative regulation of apoptosis                    bcl3; mcl1; glo1; rtkn; acvr1; becn1; hspa1a; api5; arhgdia; bcl6; bag3; rb1cc1; ywhaz; sema4d; tax1bp1; rasa1                                                                                                                                                                                                                                                                           16                  227                 0,0001
  GO:0006512   ubiquitin cycle                                     fbxo28; pcnp; trim33; fbxl11; atg12; isg15; sumo2; zc3hc1; ube2a; map1lc3b; rnf34; prpf19; spsb1; tceb1; march7; ubac1; fbxo18; klhl12; ubr4; rnf167; ube2z; mib2; fbxo6; syvn1                                                                                                                                                                                                          24                  549                 0,000184
  GO:0006606   protein import into nucleus                         bcl3; nup205; bcl6; stat1; kpna4; kpna6; pttg1ip; mcm3ap; tpr; xpo1                                                                                                                                                                                                                                                                                                                      10                  96                  0,000189
  GO:0007243   protein kinase cascade                              oxsr1; litaf; fadd; ripk2; stat1; ifnar2; mapk8ip3; rb1cc1; slc20a1; tfg; atp6ap2; bcl3; ikbkg; map2k1ip1; mib2; irak1; akap11; tbk1                                                                                                                                                                                                                                                     18                  376                 0,000448
  GO:0007249   I-kappaB kinase/NF-kappaB cascade;                  bcl3; litaf; fadd; ikbkg; ripk2; stat1; irak1; mib2; slc20a1; tfg; tbk1                                                                                                                                                                                                                                                                                                                  11                  139                 0,00078
  GO:0006928   cell motility                                       actb; nrp1; actr2; acvr1; map2k1; sdcbp; tubb2c; top2b; arhgdia; bcl6; arpc3; plaur; pxmp3; parp9; plxna3; tnfrsf12a; mkln1                                                                                                                                                                                                                                                              17                  383                 0,00269
  GO:0008283   cell proliferation                                  nrp1; map2k1; mapre1; gnl3; bcl6; e2f4; mdk; raf1; ripk2; crip2; prpf19; rbbp7; myc; capn1; gpc4; sbds; cnot8; ctnnbip1; dkc1; csk; prmt5; hdgf; tfdp1; sipa1; smad4; klf11; col18a1                                                                                                                                                                                                     27                  745                 0,00327
  GO:0007049   cell cycle                                          acvr1; map2k1; mapre1; pcnp; zw10; bcl6; e2f4; zc3hc1; ckap5; mapk6; rb1cc1; rbbp8; supt5h; tubb3; cdk5rap1; myc; rbm5; mrpl41; krt7; prmt5; hcfc1; rabgap1; ppp1cb; tfdp1; axin1; hbp1; sipa1; tusc4; rpa1                                                                                                                                                                              29                  839                 0,00484

[Table 2](#pone.0206132.t002){ref-type="table"} shows gene ontologies for 710 significantly upregulated genes in solid compared with lepidic architecture using GOstat p-value ≤ 0.005. No significant gene ontologies were resulted for the 105 downregulated genes.

Gene expression regulation was represented by RNA processing and splicing. Protein linked processes included ontologies like protein transport, protein targeting, ribonucleoprotein complex biogenesis and ubiquitin cycle. Focusing on signal transduction pathways, members of the MAPK \[mitogen-activated protein kinases) signalling (*MAP2K1*, *MAPK6*, *MAPKAPK5*, *MAP2K1IP1* and *MAPK8IP3*) and NF-κB (nuclear factor \'kappa-light-chain-enhancer\' of activated B-cells) signalling (*IKBKG*, *LITAF*, *STAT1*, *BCL3*, *TFG* and *TBK1*) were upregulated in the solid pattern.

Independent on DEseq and gene ontology analysis, known oncogenes and tumor suppressors in lung adenocarcinoma have been investigated for gene expression variance. Most of the genes were not informative on transcript level, only MET and MAP2K1 expression indicates upregulation in the solid pattern ([S5 Table](#pone.0206132.s009){ref-type="supplementary-material"}).

For IHC validation, we selected *PFKP*, *ITPKA* and *ERRFI1* upregulated in the solid pattern and *ANG* upregulated in the lepidic pattern as putative novel biomarkers in distinct predominant architectures.

Immunohistochemical validation {#sec015}
------------------------------

The pattern-specific protein expression of *ITPKA* and *angiogenin* by immunohistochemistry confirmed the RNA levels. The protein *ITPKA* was more abundant in the solid pattern, showing cytoplasmic staining, and *angiogenin* was more abundant in the lepidic pattern, showing nuclear staining. The strongest differences in protein expression between the two patterns using the H-Score was shown for *ITPKA* (p = 0.02) and *angiogenin* (p = 0.113, not significant). Cytoplasmic and nuclear expression of *PFKP* was present in both patterns, slightly more in the solid architecture (not significant). The cytoplasmic expression of *ERRFI1* remained below the 50 point H-score level for both patterns, and was slightly higher expressed in the solid architecture ([Fig 1](#pone.0206132.g001){ref-type="fig"}).

![Immunohistochemistry.\
Immunohistochemical staining of *inositol-1*,*4*,*5-trisphosphate-3-kinase-A (ITPKA)*, *phosphofructokinase*, *platelet (PFKP)*, *mitogen-inducible gene 6 (ERRFI1)* and *angiogenin (ANG)* in pulmonary adenocarcinoma with predominant lepidic (B, E, H, K) and solid growth patterns (C, F, I, L). 200x magnification. Histograms depict mean staining scores with standard deviation of n = 20 adenocarcinomas each (A, D, G, J).](pone.0206132.g001){#pone.0206132.g001}

Discussion {#sec016}
==========

For a long time, the nature of adenocarcinomas was histologically and clinically seen as a monolithic block. Clinical research within the last decade has led to a precise definition of subtypes considering growth patterns and molecular characteristics which are associated with diverse clinical outcomes \[[@pone.0206132.ref001],[@pone.0206132.ref005],[@pone.0206132.ref013]\]. However, histopathological growth patterns and prognostic diversity did not necessarily match with molecular subtypes defined by transcriptional profiles, CpG island methylation or oncogene mutations \[[@pone.0206132.ref013]\]. So far, biomarkers and molecular targets specific for tumor growth patterns have been sporadic. For example, an association was reported between higher expression of TTF-1 and the lepidic pattern \[[@pone.0206132.ref025]\]. In the solid pattern, C4.4A was reported as a surrogate marker for a poor outcome \[[@pone.0206132.ref026]\]. The objective of this project was to broaden our knowledge of the different molecular structures between distinct patterns of lung adenocarcinoma. Furthermore, this may help to establish novel biomarkers and target sites that are valuable for future individualised treatment strategies in human pulmonary adenocarcinoma. To our knowledge, we present the first screening study to identify growth pattern-specific gene signatures. Our approach included laser-captured microdissection to separate specific growth patterns in tissue sections of lung adenocarcinoma. Subsequent microarray analyses depicted transcriptome differences between the solid pattern and other growth patterns. A gene classifier could be adopted to assign all 48 gene expression profiles to previously defined molecular subtypes linked to lung adenocarcinomas. For example, the majority of solid specimens matched with the PI subtype. This association was also described in a comprehensive study including 230 adenocarcinomas \[[@pone.0206132.ref013]\]. Here, upregulated genes in the solid pattern were found to be more frequently aberrant in the PI subtype. Moreover, we suggest molecular similarities between the acinar pattern and the PP subtype as well as the lepidic pattern and the TRU subtype. Of note, both these tumor subgroups have been independently found to be prognostically favourable \[[@pone.0206132.ref005],[@pone.0206132.ref012]\].

Microarray profiles revealed a clear separation between the solid and lepidic growth patterns upon tissue microdissection. Further downstream analyses of the gene signature suggested oncogenic targets, pathways and gene ontologies in both growth patterns. Genes upregulated in the worse prognostic solid architecture were associated with cell proliferation, cell cycle activation, inhibition of apoptosis and cell motility. Our signature did not show a significant overlap with existing lung adenocarcinoma microarray data. The poor accordance with other signatures is likely reasonable since microdissected growth patterns are not readily comparable with unselected tumor tissues.

Four candidate genes were selected for IHC protein analyses according to their expression differences between the solid and the lepidic pattern. The IHC results indicated a higher abundance of *ITPKA* in the solid pattern of pulmonary adenocarcinoma. Up-regulation of *ITPKA* in tumor cell lines with low endogenous *ITPKA* expression increases migration \[[@pone.0206132.ref027]\]. *ITPKA* is preferentially expressed in cell lines derived from metastases of small cell lung cancer and squamous lung carcinoma, whereas pulmonary adenocarcinoma shows a high expression frequency of *ITPKA* in primary tumor cells. The expression of *ITPKA* in adenocarcinoma might increase the invasive potential of cancer cells. Furthermore, this enzyme is considered a potential target for anti-metastatic therapy and small molecule inhibitors \[[@pone.0206132.ref028]\]. Our results suggest *ITPKA* as a potential target for the development of targeted therapies, particular for predominant solid lung adenocarcinoma.

*Angiogenin* was shown to be up-regulated in the lepidic pattern on the RNA and protein levels. *Angiogenin* is known as a pro-angiogenic growth factor that is up-regulated in several types of cancer. Nuclear expression of *angiogenin* has been shown in about two thirds of lung adenocarcinomas, and target inhibition impairs xenograft tumor proliferation and angiogenesis \[[@pone.0206132.ref029]\]. A p53 interacting function of *angiogenin* in anti-apoptosis and survival of cancer cells suggests that targeting *angiogenin* could be an effective therapy for several cancers \[[@pone.0206132.ref030]\]. Our data indicate that *angiogenin* might be of importance in the lepidic architecture, nevertheless our findings were not statistically significant. Upregulation of *PFKP* and *ERRFI1* in the solid architecture could not be confirmed on the protein level. Possible explanations are the discordance between RNA and protein, or additional tumor characteristics as confounding factors. For example, it has been shown that *ERRFI1/MIG6* expression is associated with EMT and resistance to *EGFR* inhibitors in lung cancer xenografts \[[@pone.0206132.ref031]\].

Overall, this study presents distinct transcriptomic differences between lung adenocarcinoma growth patterns, which could be validated for the solid-expressed *ITPKA* and the lepidic-expressed *angiogenin* proteins. As a limitation, these gene signatures and putative targets could only indirectly be linked to prognosis via previously defined prognostic adenocarcinoma subgroups. Our screening and validation cohort was designed for pattern-specific expression analysis, but not adequate to include clinical follow-up data into statistical analyses. Further studies in larger cohorts of IASLC/ATS/ERS classified adenocarcinomas are needed to better understand the associations between molecular heterogeneity and clinical outcome in pulmonary adenocarcinoma.

Conclusion {#sec017}
==========

To our knowledge, this study is the first to identify growth pattern-specific gene signatures in pulmonary adenocarcinoma. With tumor profiling at the molecular level the study provides valuable new information about pulmonary adenocarcinoma and allows a better assessment of the five adenocarcinoma subgroups. As this study at hand is only a modest contribution to basic cancer research further validation of individual biomarkers and target sites in distinct histological patterns are strictliy necessary to pave the way toward novel approaches in pathological diagnostics and personalised therapy in the future.

Supporting information {#sec018}
======================

###### RIN (RNA integrity number) values of 48 samples.

Illumina chip raw data quartiles and RIN values were combined for ordered samples LC1-LC48. Left axis defines log2 expression value quartiles for each chip, numbering on the right assign RIN value for each RNA sample used for the chip.

(TIF)

###### 

Click here for additional data file.

###### Heatmap showing SVM predictions for the expression subtype for all 48 specimens in this study.

The color code indicates the class probability for each of the three expression subtypes, thus visualizing the level of confidence of the prediction. Notably, the SVM model was trained on the data by Wilkerson et al. based on the overlap of their reported signature and our chip (260 genes).

(TIF)

###### 

Click here for additional data file.

###### Multi-dimensional scaling plot of joint expression data from Wilkerson et al. (2012) and this study.

Samples from Wilkerson et al. (2012) are colored according to the expression subtype (PI (red), PP (green), TRU (black)). Samples from this study are labeled with a number, linking to [S1 Table](#pone.0206132.s005){ref-type="supplementary-material"} ("LC\_" is omitted from the text labels in this plot to save space).

(TIF)

###### 

Click here for additional data file.

###### Comparison of the transcriptomic activity between the solid and lepidic patterns.

Hierarchical clustering (Ward's method) of differentially expressed genes between the solid and lepidic growth patterns using Pearson correlation distance.

(TIF)

###### 

Click here for additional data file.

###### Differentially expressed genes between all tumor pattern comparisons.

[S1 Table](#pone.0206132.s005){ref-type="supplementary-material"} shows LIMMA analyses and the number of differentially expressed genes (FDR 5%, fold change \>1.5 or \< 0.66) between all tumor pattern comparisons.

(PDF)

###### 

Click here for additional data file.

###### Molecular subtype assignment.

[S2 Table](#pone.0206132.s006){ref-type="supplementary-material"} shows molecular subtype assignment using the reported nearest centroid subtype predictor overlap (Wilkerson PlosOne, 2012)

(PDF)

###### 

Click here for additional data file.

###### Differentially expressed non-redundant genes between solid and lepidic architecture specimens.

LIMMA analysis revealed 815 differentially expressed non-redundant genes (FDR 5%, fold change \> 1.5 or \< 0.66) between solid and lepidic architecture specimens. The gene list is ordered according to a decreasing fold change.

(PDF)

###### 

Click here for additional data file.

###### Comparison of the 50 highest upregulated genes in solid or lepidic growth pattern with published gene signatures using GeneSigDB.

[S4 Table](#pone.0206132.s008){ref-type="supplementary-material"} shows the comparison of the 50 highest upregulated genes in solid or lepidic growth pattern with published gene signatures using GeneSigDB. Table view was restricted to studies with a minimum of 20% overlap (10 genes).

(PDF)

###### 

Click here for additional data file.

###### Comparison of known lung adenocarcinoma oncogenes and tumor suppressor genes between different growth patterns.

Known lung adenocarcinoma oncogenes and tumor suppressor genes were shown with MEAN and SD expression values in all growth patterns. T-test between different growth patterns were mostly not significant (p-value \> 0.05, not adjusted). Only one group comparison indicated higher expression of MET and MAP2K1 (MEK1) in solid compared to lepidic growth pattern (p-value 0.04).

(PDF)

###### 

Click here for additional data file.
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